AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2139409 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg Acebutolol plus 20 mg Nifedipine daily (group 4)
Number of subjects: 117
Study 2139409 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg Atenolol plus 10 mg Enalapril daily (group 5)
Number of subjects: 117
Study 2139409 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 117
Study 2139409 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 117
Study 7247639 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenfluramine hydrochloride
Number of subjects: 120
Study 7247639 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined pharmacotherapy and behavior therapy
Number of subjects: 120
Study 7247639 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavior therapy alone
Number of subjects: 120
Study 7247639 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 120
Study 7247639 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavior therapy
Number of subjects: 120
Study 7247639 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacotherapy
Number of subjects: 120
Study 7247639 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment
Number of subjects: 120
Study 31567411 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral fosfomycin monotherapy for uncomplicated UTI and bacterial prostatitis
Number of subjects: 0
Study 31567411 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous fosfomycin in combination with other agents
Number of subjects: 0
Study 31567411 — intervention group
Group type: COMPARATOR
Intervention: Fosfomycin (specific details not provided)
Number of subjects: 0
Study 27095167 — intervention group
Group type: EXPERIMENTAL
Intervention: Estazolam
Number of subjects: 402
Study 27095167 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 402
Study 26775373 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol (75 mg/day)
Number of subjects: 40
Study 26775373 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol + Gabapentin (75 mg/day tramadol + 900 mg/day gabapentin)
Number of subjects: 40
Study 26775373 — intervention group
Group type: COMPARATOR
Intervention: Control group (Tramadol only)
Number of subjects: 40
Study 26775373 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (Tramadol + Gabapentin)
Number of subjects: 40
Study 25881758 — intervention group
Group type: EXPERIMENTAL
Intervention: Global Postural Reeducation (GPR)
Number of subjects: 61
Study 25881758 — intervention group
Group type: COMPARATOR
Intervention: Control (waiting list under drug treatment)
Number of subjects: 61
Study 24311316 — intervention group
Group type: EXPERIMENTAL
Intervention: S. boulardii 500 mg/day + AB
Number of subjects: 333
Study 24311316 — intervention group
Group type: EXPERIMENTAL
Intervention: S. boulardii + ORS
Number of subjects: 333
Study 21554803 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric bypass surgery (mean 30 % weight loss)
Number of subjects: 60
Study 21554803 — intervention group
Group type: EXPERIMENTAL
Intervention: Duodenal switch surgery (mean 41 % weight loss)
Number of subjects: 60
Study 21554803 — intervention group
Group type: COMPARATOR
Intervention: Healthy persons (BMI 17‐31 kg/m(2))
Number of subjects: 60
Study 18647982 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (50 mg adjustable to 100 mg before sexual activity)
Number of subjects: 98
Study 18647982 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study 18647982 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil and Placebo
Number of subjects: 98
Study 16575013 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate counseling
Number of subjects: 60
Study 14740953 — intervention group
Group type: EXPERIMENTAL
Intervention: Monovalent live‐attenuated dengue virus (DENV) vaccine candidates
Number of subjects: 69
Study 10674459 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadodiamide injection at a dosage of 0.1 mmol/kg body weight
Number of subjects: 59
Study 10674459 — intervention group
Group type: COMPARATOR
Intervention: No contrast (control group)
Number of subjects: 59
Study 9846855 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose vitamin A (200,000 IU; 100,000 IU if aged <12 mo)
Number of subjects: 900
Study 9846855 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose vitamin A (5000 IU/d until discharge)
Number of subjects: 900
Study 9846855 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 900
Study 7905256 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive imipramine hydrochloride (mean, 233 +/- 72 mg/d)
Number of subjects: 24
Study 7905256 — intervention group
Group type: COMPARATOR
Intervention: Placebo substitution
Number of subjects: 24
Study 2645914 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine 30 mg tid
Number of subjects: 234
Study 2645914 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 40 mg tid
Number of subjects: 234
Study 2645914 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine 30 mg tid and Propranolol 40 mg tid
Number of subjects: 234
Study 1097295 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine (1.5 mg per kg)
Number of subjects: 30
Study 1097295 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 31027246 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeinated gel (300 mg of caffeine)
Number of subjects: 17
Study 28974184 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoanalytic psychotherapy
Number of subjects: 93
Study 28974184 — intervention group
Group type: COMPARATOR
Intervention: Minimal supportive treatment/waitlist control
Number of subjects: 93
Study 26089546 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous vitamin C
Number of subjects: 38
Study 26089546 — intervention group
Group type: COMPARATOR
Intervention: Saline-sham
Number of subjects: 38
Study 23473396 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinolysis with bolus tenecteplase (half dose for patients ≥75 years), clopidogrel, and enoxaparin before transport to a PCI-capable hospital.
Number of subjects: 1892
Study 23473396 — intervention group
Group type: COMPARATOR
Intervention: Primary PCI
Number of subjects: 1892
Study 23473396 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinolysis
Number of subjects: 1892
Study 21554679 — intervention group
Group type: EXPERIMENTAL
Intervention: IV infusion of salbutamol (15 μg kg ideal body weight‐1 hr‐1)
Number of subjects: 1334
Study 21554679 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% sodium chloride solution)
Number of subjects: 1334
Study 17852392 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose NovaSil (3.0 g NS day(-1))
Number of subjects: 177
Study 17852392 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose NovaSil (1.5 g NS day(-1))
Number of subjects: 177
Study 17852392 — intervention group
Group type: COMPARATOR
Intervention: Placebo-control (0 g NS day(-1))
Number of subjects: 177
Study 16715252 — intervention group
Group type: COMPARATOR
Intervention: Topical ofloxacin 0.3%
Number of subjects: 16
Study 16715252 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical levofloxacin 0.5%
Number of subjects: 16
Study 14579081 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body PET
Number of subjects: 188
Study 14579081 — intervention group
Group type: COMPARATOR
Intervention: Conventional work-up (CWU)
Number of subjects: 188
Study 10707753 — intervention group
Group type: EXPERIMENTAL
Intervention: GIK infusion
Number of subjects: 21
Study 10707753 — intervention group
Group type: COMPARATOR
Intervention: Saline solution (Control)
Number of subjects: 21
Study 9112894 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy
Number of subjects: 83
Study 9112894 — intervention group
Group type: COMPARATOR
Intervention: Open cholecystectomy
Number of subjects: 83
Study 7814116 — intervention group
Group type: EXPERIMENTAL
Intervention: Atraumatic Restorative Treatment (ART) technique
Number of subjects: 3
Study 7814116 — intervention group
Group type: COMPARATOR
Intervention: Restorative care (amalgam fillings)
Number of subjects: 3
Study 7814116 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 3
Study 2735592 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mL/kg normal saline infusion over 45 minutes
Number of subjects: 20
Study 2735592 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mL/kg normal saline infusion over one hour (after first infusion)
Number of subjects: 20
Study 2735592 — intervention group
Group type: COMPARATOR
Intervention: 20 mL/kg normal saline infusion over 45 minutes (Group B)
Number of subjects: 20
Study 2735592 — intervention group
Group type: COMPARATOR
Intervention: 15 mL/kg normal saline infusion over three hours (after first infusion)
Number of subjects: 20
Study 31784345 — intervention group
Group type: EXPERIMENTAL
Intervention: Saury oil (12 g; 3.5 g of LCMUFA and 3.4 g of omega-3 FAs)
Number of subjects: 30
Study 31784345 — intervention group
Group type: EXPERIMENTAL
Intervention: Saury oil
Number of subjects: 30
Study 31784345 — intervention group
Group type: COMPARATOR
Intervention: Control oil (identical capsules with a mixture of sardine and olive oil; 4.9 g of shorter-chain MUFA oleate and 3 g of omega-3 FAs)
Number of subjects: 30
Study 31062094 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymphocyte-monocyte-neutrophil score (LMN score) based on preoperative absolute counts of neutrophils, lymphocytes, and monocytes.
Number of subjects: 445
Study 27229178 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin/metformin fixed-dose combination (Sita/Met)
Number of subjects: 292
Study 27229178 — intervention group
Group type: COMPARATOR
Intervention: Glimepiride
Number of subjects: 292
Study 25487222 — intervention group
Group type: EXPERIMENTAL
Intervention: Optical coherence tomography guidance
Number of subjects: 101
Study 25487222 — intervention group
Group type: COMPARATOR
Intervention: Angiography guidance
Number of subjects: 101
Study 23337655 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser acupuncture
Number of subjects: 47
Study 23337655 — intervention group
Group type: COMPARATOR
Intervention: Placebo laser
Number of subjects: 47
Study 22040190 — intervention group
Group type: EXPERIMENTAL
Intervention: Osmotic-release oral system methylphenidate (OROS-MPH)
Number of subjects: 303
Study 22040190 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 303
Study 18436340 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Negotiation Interview
Number of subjects: 494
Study 18436340 — intervention group
Group type: COMPARATOR
Intervention: Discharge Instructions
Number of subjects: 494
Study 16494088 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil
Number of subjects: 35
Study 12917228 — intervention group
Group type: EXPERIMENTAL
Intervention: Early diagnosis (screened) group
Number of subjects: 103
Study 12917228 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 103
Study 10688506 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 microg misoprostol orally every 4 hours to a maximum of three doses
Number of subjects: 80
Study 10688506 — intervention group
Group type: COMPARATOR
Intervention: Intravenous oxytocin infusion according to the hospital protocol
Number of subjects: 80
Study 9352869 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymphoblastoid IFN-alpha (higher dosage and longer period)
Number of subjects: 92
Study 9352869 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymphoblastoid IFN-alpha (same schedule)
Number of subjects: 92
Study 9352869 — intervention group
Group type: COMPARATOR
Intervention: Initial nonresponders (no retreatment)
Number of subjects: 92
Study 1386386 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial factors assessed at the beginning of the study
Number of subjects: 476
Study 1386386 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-employment
Number of subjects: 476
Study 1386386 — intervention group
Group type: EXPERIMENTAL
Intervention: Free-floating anxiety
Number of subjects: 476
Study 1386386 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal back pain locus of control
Number of subjects: 476
Study 1386386 — intervention group
Group type: EXPERIMENTAL
Intervention: Beliefs in control by others
Number of subjects: 476
Study 1386386 — intervention group
Group type: EXPERIMENTAL
Intervention: Accomplishment of back exercises
Number of subjects: 476
Study 4070645 — intervention group
Group type: EXPERIMENTAL
Intervention: Amineptine
Number of subjects: 34
Study 4070645 — intervention group
Group type: COMPARATOR
Intervention: Clomipramine
Number of subjects: 34
Study 31423687 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemical cardioversion with procainamide infusion
Number of subjects: 84
Study 31423687 — intervention group
Group type: COMPARATOR
Intervention: Electrical cardioversion
Number of subjects: 84
Study 31423687 — intervention group
Group type: EXPERIMENTAL
Intervention: Both strategies
Number of subjects: 84
Study 29631782 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab (60 mg subcutaneous every 6 months)
Number of subjects: 795
Study 29631782 — intervention group
Group type: COMPARATOR
Intervention: Risedronate (5 mg oral daily)
Number of subjects: 795
Study 29631782 — intervention group
Group type: COMPARATOR
Intervention: Both Denosumab and Risedronate
Number of subjects: 795
Study 29631782 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab
Number of subjects: 795
Study 27876038 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived availability of built environment structures
Number of subjects: 610
Study 27876038 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived condition of built environment structures
Number of subjects: 610
Study 27876038 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived safety of built environment structures
Number of subjects: 610
Study 23597109 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg/day citalopram for 7 days
Number of subjects: 0
Study 23597109 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 7 days
Number of subjects: 0
Study 22677878 — intervention group
Group type: EXPERIMENTAL
Intervention: C-MAC videolaryngoscope
Number of subjects: 130
Study 22677878 — intervention group
Group type: COMPARATOR
Intervention: McGrath videolaryngoscope
Number of subjects: 130
Study 20626147 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) combined with small dose of clozapine (50 mg/d to 100‐150 mg/d, 3 times a week for 8 weeks)
Number of subjects: 80
Study 20626147 — intervention group
Group type: COMPARATOR
Intervention: Conventional oral administration of clozapine (50‐100 mg/d to 200‐500 mg/d, for 8 weeks)
Number of subjects: 80
Study 20626147 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) combined with small dose of clozapine
Number of subjects: 80
Study 19093056 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular 2-implant overdenture (IOD)
Number of subjects: 162
Study 19093056 — intervention group
Group type: COMPARATOR
Intervention: New conventional denture (CD)
Number of subjects: 162
Study 16224525 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol combined with epidural block
Number of subjects: 30
Study 16224525 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol and remifentanil (plasma concentration 4 microg/L)
Number of subjects: 30
Study 16224525 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol and remifentanil (plasma concentration 7 microg/L)
Number of subjects: 30
Study 16224525 — intervention group
Group type: EXPERIMENTAL
Intervention: Target-controlled infusion using propofol with Marsh parameters
Number of subjects: 30
Study 12005077 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk basic protein (MBP) 40 mg per day
Number of subjects: 33
Study 12005077 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 10068928 — intervention group
Group type: EXPERIMENTAL
Intervention: UVA1 therapy
Number of subjects: 70
Study 10068928 — intervention group
Group type: EXPERIMENTAL
Intervention: UVA1 cold light therapy
Number of subjects: 70
Study 10068928 — intervention group
Group type: COMPARATOR
Intervention: Combined UVA-UVB therapy
Number of subjects: 70
Study 10068928 — intervention group
Group type: EXPERIMENTAL
Intervention: UVA1 therapy (4 weeks post-treatment)
Number of subjects: 70
Study 10068928 — intervention group
Group type: COMPARATOR
Intervention: UVA-UVB therapy
Number of subjects: 70
Study 7586348 — intervention group
Group type: EXPERIMENTAL
Intervention: Palmaz‐Schatz coronary stent implantation
Number of subjects: 207
Study 7586348 — intervention group
Group type: COMPARATOR
Intervention: Conventional balloon angioplasty (PTCA)
Number of subjects: 207
Study 2405291 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose intravenous immunoglobulin (IVIg)
Number of subjects: 7
Study 2405291 — intervention group
Group type: COMPARATOR
Intervention: Placebo (albumin)
Number of subjects: 7
Study 6764120 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole
Number of subjects: 111
Study 6764120 — intervention group
Group type: COMPARATOR
Intervention: OK-432
Number of subjects: 111
Study 6764120 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 111
Study 31706550 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional intervention (pediatric-focused posters)
Number of subjects: 0
Study 31706550 — intervention group
Group type: EXPERIMENTAL
Intervention: Front-line ownership (FLO) intervention
Number of subjects: 0
Study 31706550 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard intervention)
Number of subjects: 0
Study 31706550 — intervention group
Group type: EXPERIMENTAL
Intervention: FLO intervention
Number of subjects: 0
Study 31148155 — intervention group
Group type: EXPERIMENTAL
Intervention: Amustaline-Glutathione (A-GSH) RBCC
Number of subjects: 80
Study 31148155 — intervention group
Group type: COMPARATOR
Intervention: Control RBCC
Number of subjects: 80
Study 31148155 — intervention group
Group type: EXPERIMENTAL
Intervention: A-GSH RBCC
Number of subjects: 80
Study 31148155 — intervention group
Group type: COMPARATOR
Intervention: A-GSH RBCC and Control RBCC
Number of subjects: 80
Study 28419855 — intervention group
Group type: EXPERIMENTAL
Intervention: Silymarin (700 mg, 3 times daily for 48 weeks)
Number of subjects: 99
Study 28419855 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study 25791707 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium alendronate
Number of subjects: 26
Study 25791707 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium fluoride
Number of subjects: 26
Study 25791707 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 26030948 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy of ultrasound and TENS
Number of subjects: 115
Study 26030948 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy (either ultrasound or TENS)
Number of subjects: 115
Study 20857170 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib 1,500 mg PO daily
Number of subjects: 32
Study 20857170 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 19500005 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 537
Study 19500005 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture combined with drugs
Number of subjects: 537
Study 17434599 — intervention group
Group type: EXPERIMENTAL
Intervention: Mood stabilizer treatment
Number of subjects: 111
Study 17434599 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar manic patients
Number of subjects: 111
Study 15078000 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemifloxacin (320 mg)
Number of subjects: 12
Study 15078000 — intervention group
Group type: COMPARATOR
Intervention: Clarithromycin (500 mg)
Number of subjects: 12
Study 11214127 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol 4.5 microg as needed
Number of subjects: 362
Study 11214127 — intervention group
Group type: COMPARATOR
Intervention: Terbutaline 0.5 mg as needed
Number of subjects: 362
Study 9453275 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe attack definition
Number of subjects: 276
Study 9453275 — intervention group
Group type: EXPERIMENTAL
Intervention: Migraine sufferers with at least one severe attack
Number of subjects: 276
Study 7938398 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual captopril
Number of subjects: 12
Study 3340574 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensity-controlled, graded dance exercise with individual and group reinforcement
Number of subjects: 38
Study 3340574 — intervention group
Group type: COMPARATOR
Intervention: Moderate intensity exercise typical of commercial fitness classes with no special reinforcement
Number of subjects: 38
Study 29452110 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening doors and windows with wire meshes in 46 houses
Number of subjects: 92
Study 29452110 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 92
Study 27267081 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib monotherapy
Number of subjects: 177
Study 25850968 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg/day (monotherapy)
Number of subjects: 411
Study 25850968 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg/day + Metformin ≥1500 mg/day (add-on therapy)
Number of subjects: 411
Study 23349117 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical model
Number of subjects: 0
Study 23349117 — intervention group
Group type: COMPARATOR
Intervention: Textbooks
Number of subjects: 0
Study 23349117 — intervention group
Group type: COMPARATOR
Intervention: 3D computer model
Number of subjects: 0
Study 20616321 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular treatment
Number of subjects: 612
Study 20616321 — intervention group
Group type: COMPARATOR
Intervention: Neurosurgery
Number of subjects: 612
Study 18416404 — intervention group
Group type: EXPERIMENTAL
Intervention: Early parenting intervention
Number of subjects: 185
Study 16869994 — intervention group
Group type: EXPERIMENTAL
Intervention: Fermented gruel with live L. plantarum 299v
Number of subjects: 24
Study 16869994 — intervention group
Group type: COMPARATOR
Intervention: Pasteurised fermented gruel
Number of subjects: 24
Study 16869994 — intervention group
Group type: COMPARATOR
Intervention: Non-fermented gruel with added organic acids
Number of subjects: 24
Study 16869994 — intervention group
Group type: COMPARATOR
Intervention: pH-adjusted non-fermented gruel
Number of subjects: 24